527 related articles for article (PubMed ID: 29326121)
1. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
2. Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy.
Ferrarini M; Steimberg N; Ponzoni M; Belloni D; Berenzi A; Girlanda S; Caligaris-Cappio F; Mazzoleni G; Ferrero E
PLoS One; 2013; 8(8):e71613. PubMed ID: 23990965
[TBL] [Abstract][Full Text] [Related]
3. Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system.
Belloni D; Ferrarini M; Ferrero E; Guzzeloni V; Barbaglio F; Ghia P; Scielzo C
STAR Protoc; 2022 Sep; 3(3):101601. PubMed ID: 35990738
[TBL] [Abstract][Full Text] [Related]
4. 3D-Dynamic Culture Models of Multiple Myeloma.
Ferrarini M; Steimberg N; Boniotti J; Berenzi A; Belloni D; Mazzoleni G; Ferrero E
Methods Mol Biol; 2017; 1612():177-190. PubMed ID: 28634943
[TBL] [Abstract][Full Text] [Related]
5. Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma.
Faid L; Van Riet I; De Waele M; Facon T; Schots R; Lacor P; Van Camp B
Eur J Haematol; 1996 Nov; 57(5):349-58. PubMed ID: 9003475
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
Bar-Natan M; Stroopinsky D; Luptakova K; Coll MD; Apel A; Rajabi H; Pyzer AR; Palmer K; Reagan MR; Nahas MR; Karp Leaf R; Jain S; Arnason J; Ghobrial IM; Anderson KC; Kufe D; Rosenblatt J; Avigan D
Br J Haematol; 2017 Mar; 176(6):929-938. PubMed ID: 28107546
[TBL] [Abstract][Full Text] [Related]
7. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.
Wang X; Li C; Ju S; Wang Y; Wang H; Zhong R
Leuk Lymphoma; 2011 Oct; 52(10):1991-8. PubMed ID: 21718132
[TBL] [Abstract][Full Text] [Related]
8. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.
Jakubikova J; Cholujova D; Hideshima T; Gronesova P; Soltysova A; Harada T; Joo J; Kong SY; Szalat RE; Richardson PG; Munshi NC; Dorfman DM; Anderson KC
Oncotarget; 2016 Nov; 7(47):77326-77341. PubMed ID: 27764795
[TBL] [Abstract][Full Text] [Related]
9. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
Kikuchi J; Koyama D; Mukai HY; Furukawa Y
Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
[TBL] [Abstract][Full Text] [Related]
10. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
11. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
12. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
[TBL] [Abstract][Full Text] [Related]
13. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
[TBL] [Abstract][Full Text] [Related]
14. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.
de la Puente P; Muz B; Gilson RC; Azab F; Luderer M; King J; Achilefu S; Vij R; Azab AK
Biomaterials; 2015 Dec; 73():70-84. PubMed ID: 26402156
[TBL] [Abstract][Full Text] [Related]
15. Endosteal and Perivascular Subniches in a 3D Bone Marrow Model for Multiple Myeloma.
Braham MVJ; Ahlfeld T; Akkineni AR; Minnema MC; Dhert WJA; Öner FC; Robin C; Lode A; Gelinsky M; Alblas J
Tissue Eng Part C Methods; 2018 May; 24(5):300-312. PubMed ID: 29652626
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
17. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
18. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma.
Braham MV; Deshantri AK; Minnema MC; Öner FC; Schiffelers RM; Fens MH; Alblas J
Int J Nanomedicine; 2018; 13():8105-8118. PubMed ID: 30555229
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma.
Waldschmidt JM; Fruttiger SJ; Wider D; Jung J; Thomsen AR; Hartmann TN; Duyster J; Hug MJ; Azab KA; Jung M; Wäsch R; Engelhardt M
J Cancer Res Clin Oncol; 2022 May; 148(5):1045-1055. PubMed ID: 35072775
[TBL] [Abstract][Full Text] [Related]
20. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]